Forum Life Science 2007

14.15 - 14.40




14.40 - 15.05




15.05 - 15.30 

Strategies in drug development - Three lessons from the viewpoint of product oriented Biotech companies
Dr. Karsten Henco
CEO, U3 Pharma AG, Martinsried

Alliance management between Pharma and Biotech
Dr. Thomas Mummenbrauer
Director Business Development, GlaxoSmithKline Biologicals, Rixensart, Belgium

Strategies in drug development - Perspectives of an Indian pharmaceutical company
Dr. Ramani Aiyer
Vice President, Nicholas Piramal India Ltd., Mumbai, India

16.10 - 16.35




16.35 - 17.00



17.00 - 17.25





17.25 - 17.50

Metabolomics and systems biology for identification of novel targets
Prof. Dr. Peter Oefner
Institute of Functional Genomics, University of Regensburg

Development of novel drugs based on vascular targeting
Dr. Uwe Michaelis
Vice President Research, MediGene AG, Martinsried

CpG oligonucleotides as toll-like receptor (TLR) therapeutics
Dr. Christian Schetter
Vice President European Operations, Coley Pharmaceuticals Group, Wellesley (MA), USA/Langenfeld

DNA methyltransferases as targets of epigenetic cancer therapy
Prof. Dr. Frank Lyko
Epigenetics, German Cancer Research Center (DKFZ), Heidelberg

10.45 – 11.10




11.10 - 11.35





11.35 – 12.00





12.00 - 12.25

 


12.25 - 12.50

Current examples and future perspectives in personalised medicine
Dr. Thomas Baier
Head of Global Marketing, Roche Applied Science, Penzberg 

The "Blood Donor Biobank"- A new appoach for developing biomarkers
Dr. Silke Martin
Head of Biobank Department, Bavarian Red Cross Blood Bank, Munich

Identification of biomarkers and targets for diagnosis and therapy
Dr. Andreas Weith
Director Functional Genomics, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach a. d. Riss

Development of therapeutic antibodies
Dr. Paul W.H.I. Parren
Executive Vice President & Chief Scientific Officer, Genmab A/S, Copenhagen, Denmark

Development and clinical tests of trifunctional antibodies for cancer therapy
Dr. Hans Bochtler
CSO and Executive Vice President, Fresenius Biotech GmbH, Munich

14.15 - 14.40




14.40 – 15.05







15.05 - 15.30




15.30 – 15.55



15.55 – 16.20

Novel delivery systems for biotech medicine
Prof. Dr. Daan J. A. Crommelin
Scientific Director, Dutch Top Institute Pharma / Chairman of the Scientific Advisory Board, Octoplus, Leiden, The Netherlands

Smart drug delivery systems for bone regeneration
Dr. Andreas Schütz
Director Pharmaceutical Development, Scil Technology GmbH, Martinsried
Prof. Dr. Wolfgang Frieß
Department of Pharmacy, Pharmaceutical Technology and Biopharmaceutics, Ludwig Maximilians University Munich

Perspectives on stem cell therapy
Dr. Erik Miljan
Head of Stem Cell Discovery, ReNeuron Group plc, Guildford, Surrey, United Kingdom 

Cell based immuntherapy
Prof. Dr. Reinhard Andreesen, Prof. Dr. Andreas Mackensen Department of Hematology/Oncology, University of Regensburg

Proliferation of primary antigen specific T cells
Dr. Stephan Meier
Bayer Technology Services GmbH, Leverkusen
Prof. Dr. Rainer Buchholz
Institute of Bioprocess Engineering, University of Erlangen-Nuremberg